Incidence, and Survival Medical Expenditure of Patients With Multiple Sclerosis

Multiple sclerosis (MS) is a disease of autoimmune system which attacks the central nervous system and that is one of the most common inflammatory diseases and has caused a heavy disease burden on patients. In the world, the prevalence of MS is on the rise, and the annual growth rate of MS patients in Taiwan is much higher than the whole world (3.78 times). However, it has no discussion or study in references at present, and it is worthwhile to research. MS is not a fatal disease, but its complications make the mortality of its patients three times higher than that of general population. This study will explore the survival and the causes of death for MS patients in Taiwan by cohort study of fourteen years. In addition, in the recent years, the MS patients in Taiwan and the medical resource consumption has increased largely, and it is necessary to conduct the research.

Study Overview

• Status: Unknown
• Conditions: Neurologic Signs and Symptoms

Detailed Description

The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'. First, the investigators will perform the statistical analysis of the incidence, the prevalence, the mortality and the trend analysis of the MS patients diagnosed each year. First, Kaplan-Meier method will be employed to examine the survival curves. Next, Cox proportional hazards model will be used to analyze the survival and related factors. Last, multiple regression analysis will be then performed to analyze the influence of independent variables on patients' medical utilization in each year.

In response to the lack of data on population-based epidemiological studies on MS diseases in Asia, this research wishes to fill the gaps in the studies of global prevention and analyze the patient's survival, mortality risk factors and the medical utilization as a reference for national health policies.

• Study Type: Observational
• Enrollment (Anticipated): 2000

Contacts and Locations

Study Locations

• Taiwan
  • Taichung, Taiwan, 404
    • Genetic and Rare Disease Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare.

Description

Inclusion Criteria:

• The subjects are diagnosed as MS patients

Exclusion Criteria:

• The subjects are not diagnosed as MS patients

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
The subjects are diagnosed as MS patient; The study population is based on the 'National Health Insurance Research Database' (NHIRD) from 2001 to 2015 provided by Taiwan Ministry of Health and Welfare. The subjects are diagnosed as MS patients based on the 'Registry for Catastrophic Illness'.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence, and SurvivalMedical Expenditure of Patients with Multiple Sclerosis	we will perform the statistical analysis of the incidence, the prevalence, the mortality and the trend analysis of the MS patients diagnosed each year. First, Kaplan-Meier method will be employed to examine the survival curves. Next, Cox proportional hazards model will be used to analyze the survival and related factors. Last, multiple regression analysis will be then performed to analyze the influence of independent variables on patients' medical utilization in each year.	'National Health Insurance Research Database' (NHIRD) from 2001 to 2015

Collaborators and Investigators

• Sponsor: Chun-Ming Liao

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2019
• Primary Completion (Anticipated): May 20, 2020
• Study Completion (Anticipated): May 20, 2020

Study Registration Dates

• First Submitted: July 15, 2019
• First Submitted That Met QC Criteria: July 16, 2019
• First Posted (Actual): July 17, 2019

Study Record Updates

• Last Update Posted (Actual): July 17, 2019
• Last Update Submitted That Met QC Criteria: July 16, 2019
• Last Verified: July 1, 2019

More Information

Terms related to this study

• Keywords: multiple sclerosis; Survival Analysis; cause of death; medical resources
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Multiple Sclerosis; Sclerosis; Neurologic Manifestations
• Other Study ID Numbers: CMUH108-REC2-084

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No